ArticlePharmaceutics2021

Preclinical Toxicity and Safety of MM-129-First-in-Class BTK/PD-L1 Inhibitor as a Potential Candidate against Colon Cancer.

Justyna Magdalena Hermanowicz et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.